FIELD: medicine.
SUBSTANCE: present invention relates to a compound of the general formula (I) or to its pharmaceutically acceptable salt, where R1 is cyclopropyl, where R1 is substituted with one or two groups selected from a group consisting of halogen, C1-C3 hydroxyalkyl, and C1-C3 halogenalkyl, R2 and R3 are independently -H or halogen, R4 is phenyl or heteroaryl, which is a monocyclic or bicyclic group with 4-8 ring atoms of carbon and, in addition to ring atoms of carbon, with 1 to 3 heteroatoms selected from N and S, where R4 is optionally substituted with one, two or three groups selected from a group consisting of halogen, hydroxyl, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 halogenalkyl, C1-C3 hydroxyalkyl, -NRaRb, -NRaC(=O)Rb, -NRaC(=O)Orb, -ORa, -CN, -C(=O)Ra, -OC(=O)NRaRb, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, and Ra and Rb are independently -H or C1-C3 alkyl. The invention also relates to a pharmaceutical composition having inhibitory activity relatively to c-abl-kinase based on a compound of the formula (I).
EFFECT: new compounds and a pharmaceutical composition based on them are obtained, which can be used in medicine for the treatment of neurodegenerative diseases.
25 cl, 7 dwg, 5 tbl, 123 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS OF PYRIDAZINAMIDE AND THEIR USE AS SYNTHETIC SYNECKINASIS INHIBITORS (SYK) | 2013 |
|
RU2627661C2 |
| NEW COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL COMPOSITION INCLUDING SUCH COMPOUNDS | 2014 |
|
RU2634694C2 |
| 5-(7H-PYRROLO[2,3-d]PYRIMIDINE-4-YL)-5-AZASPIRO[2.5]OCTANE-8-CARBOXYLIC ACID DERIVATIVES AS NEW JAK-KINASE INHIBITORS | 2018 |
|
RU2761626C2 |
| TRANSGLUTAMINASE 2 (TG2) INHIBITORS | 2019 |
|
RU2781370C2 |
| PYRAZOLOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | 2015 |
|
RU2733400C2 |
| 5,6-CONDENSED BICYCLIC COMPOUNDS AND COMPOSITIONS FOR TREATING PARASITIC DISEASES | 2018 |
|
RU2738647C1 |
| PROTEOLYSIS MODULATORS AND RELATED USES | 2019 |
|
RU2805511C2 |
| THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | 2014 |
|
RU2703273C2 |
| QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2 NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS AND USE THEREOF | 2012 |
|
RU2610262C2 |
| NOVEL COMPOUNDS | 2015 |
|
RU2691389C2 |
